AMERICAN BIO MEDICA CORP

2023 Q2 Form 10-Q Financial Statement

#000165495423007911 Filed on June 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.00K $17.00K
YoY Change 300.0% -73.02%
Cash & Equivalents $68.00K $17.00K
Short-Term Investments
Other Short-Term Assets $0.00 $64.00K
YoY Change -100.0% -54.61%
Inventory $0.00 $419.0K
Prepaid Expenses
Receivables $89.00K $138.0K
Other Receivables $502.0K $400.0K
Total Short-Term Assets $659.0K $1.038M
YoY Change -36.51% -0.95%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $504.0K
YoY Change -100.0% -14.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $21.00K
YoY Change -100.0% 0.0%
Total Long-Term Assets $0.00 $527.0K
YoY Change -100.0% -26.7%
TOTAL ASSETS
Total Short-Term Assets $659.0K $1.038M
Total Long-Term Assets $0.00 $527.0K
Total Assets $659.0K $1.565M
YoY Change -57.89% -11.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $572.0K $843.0K
YoY Change -32.15% 34.02%
Accrued Expenses $338.0K $570.0K
YoY Change -40.7% -15.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.333M
YoY Change -100.0% 131.02%
Long-Term Debt Due $175.0K $1.458M
YoY Change -88.0% 13.02%
Total Short-Term Liabilities $1.117M $2.871M
YoY Change -61.09% -9.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $2.000K
YoY Change -100.0% -93.55%
Total Long-Term Liabilities $0.00 $2.000K
YoY Change -100.0% -93.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.117M $2.871M
Total Long-Term Liabilities $0.00 $2.000K
Total Liabilities $1.117M $2.873M
YoY Change -61.12% -10.16%
SHAREHOLDERS EQUITY
Retained Earnings -$23.34M -$24.19M
YoY Change -3.51%
Common Stock $481.0K $481.0K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$458.0K -$1.308M
YoY Change
Total Liabilities & Shareholders Equity $659.0K $1.565M
YoY Change -57.89% -11.43%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
110000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
60000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
769000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000896747
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
466000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48098476 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48098476 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48098476 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-28666
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
AMERICAN BIO MEDICA CORPORATION
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NY
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
14-1702188
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
122 Smith Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Kinderhook
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
12106
CY2023Q1 dei City Area Code
CityAreaCode
518
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
758-8158
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
ABMC
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48098476 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
89000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
82000 usd
CY2023Q1 us-gaap Inventory Adjustments
InventoryAdjustments
0 usd
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
235000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
379000 usd
CY2023Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
202000 usd
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
202000 usd
CY2023Q1 abmc Retention Fund Receivable Asset Sale
RetentionFundReceivableAssetSale
300000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
0 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
72000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
659000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000 usd
CY2023Q1 us-gaap Assets
Assets
659000 usd
CY2022Q4 us-gaap Assets
Assets
1269000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
572000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
760000 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
338000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
514000 usd
CY2023Q1 abmc Right Of Use Liabilities Operating Leases Current
RightOfUseLiabilitiesOperatingLeasesCurrent
0 usd
CY2022Q4 abmc Right Of Use Liabilities Operating Leases Current
RightOfUseLiabilitiesOperatingLeasesCurrent
4000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
32000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
94000 usd
CY2023Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
175000 usd
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2230000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1117000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3602000 usd
CY2023Q1 abmc Right Of Use Liabilities Operating Leasesnoncurrent
RightOfUseLiabilitiesOperatingLeasesnoncurrent
0 usd
CY2022Q4 abmc Right Of Use Liabilities Operating Leasesnoncurrent
RightOfUseLiabilitiesOperatingLeasesnoncurrent
6000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1117000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3608000 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48098476 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
481000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
481000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22403000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22403000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23342000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25223000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-458000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2339000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
659000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1269000 usd
CY2023Q1 us-gaap Revenues
Revenues
164000 usd
CY2022Q1 us-gaap Revenues
Revenues
351000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
90000 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
323000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
74000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
28000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22000 usd
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20000 usd
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
42000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
238000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
295000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
286000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
359000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-212000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-331000 usd
CY2023Q1 abmc Asset Valuation Loss
AssetValuationLoss
921000 usd
CY2022Q1 abmc Asset Valuation Loss
AssetValuationLoss
0 usd
CY2023Q1 abmc Asset Sale Other Income
AssetSaleOtherIncome
-3035000 usd
CY2022Q1 abmc Asset Sale Other Income
AssetSaleOtherIncome
0 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
21000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
48000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2093000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1881000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-379000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1881000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-379000 usd
CY2023Q1 abmc Basic And Diluted Income Loss Per Common Share
BasicAndDilutedIncomeLossPerCommonShare
0.04
CY2022Q1 abmc Basic And Diluted Income Loss Per Common Share
BasicAndDilutedIncomeLossPerCommonShare
-0.01
CY2023Q1 abmc Weighted Average Number Of Shares Outstanding Basic Diluted
WeightedAverageNumberOfSharesOutstandingBasicDiluted
48098476 shares
CY2022Q1 abmc Weighted Average Number Of Shares Outstanding Basic Diluted
WeightedAverageNumberOfSharesOutstandingBasicDiluted
47770698 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2339000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1881000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-458000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-944000 usd
CY2022Q1 abmc Shares Issued In Connection With Landmark Consulting Agreement Amount
SharesIssuedInConnectionWithLandmarkConsultingAgreementAmount
15000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-379000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1308000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1881000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-379000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
13000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-2114000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1000 usd
CY2023Q1 abmc Consulting Fee Paid With Restricted Stock
ConsultingFeePaidWithRestrictedStock
0 usd
CY2022Q1 abmc Consulting Fee Paid With Restricted Stock
ConsultingFeePaidWithRestrictedStock
15000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
186000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
83000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
0 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
161000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-176000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-17000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
9000 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-62000 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-363000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13000 usd
CY2023Q1 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
247000 usd
CY2022Q1 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
247000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
100000 usd
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
250000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
462000 usd
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
547000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-85000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
34000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-98000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17000 usd
CY2023Q1 abmc Non Cash Transactions Consulting Fee Paid With Restricted Stock
NonCashTransactionsConsultingFeePaidWithRestrictedStock
0 usd
CY2022Q1 abmc Non Cash Transactions Consulting Fee Paid With Restricted Stock
NonCashTransactionsConsultingFeePaidWithRestrictedStock
15000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
41000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
46000 usd
CY2023Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note A - Basis of Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2023, and the results of operations and cash flows for the three month periods ended March 31, 2023 (the “First Quarter 2023”) and March 31, 2022 (the “First Quarter 2022”).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Operating results for the First Quarter 2023 are not indicative of results that will be reported for the year ending December 31, 2023 as the Company sold substantially all of its assets on February 28, 2023 to Healgen Scientific, LLC (“Healgen”). Amounts at December 31, 2022 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the First Quarter 2023, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of liabilities, expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company evaluates estimates, including those related to bad debts, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances and amounts expected from its receivables (including the Employee retention Credit receivable and the retention (escrow) proceeds from the asset sale) may not be sufficient to fund the Company through May 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) were paid in full with proceeds from the asset sale on February 28, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Recently Adopted Accounting Standards</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations,</span> issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 became effective on January 1, 2023. The Company adopted ASU 2022-04 on January 1, 2023 and the adoption did not have an impact on the Company’s financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">ASU 2016-13, Financial Instruments—Credit Losses (Topic 326)</span>; <span style="text-decoration:underline">Measurement of Credit Losses on Financial Instruments</span>, issued in June 2016, requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted ASU 2016-13 on January 1, 2023 and the adoption did not have a material impact on the Company’s financial condition or results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Accounting Standards Issued; Not Yet Adopted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span>, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.</p>
CY2023Q1 abmc Accounting Standards Issued Not Yet Adopted
AccountingStandardsIssuedNotYetAdopted
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span>, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.</p>
CY2023Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
532000 usd
CY2022Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
91000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
0 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
444000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
235000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
379000 usd
CY2023Q1 us-gaap Land
Land
0 usd
CY2022Q4 us-gaap Land
Land
102000 usd
CY2023Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
0 usd
CY2022Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
1352000 usd
CY2023Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
0 usd
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2110000 usd
CY2023Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
0 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
412000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3976000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3510000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
466000 usd
CY2023Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
11427000 usd
CY2023Q1 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
26000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
16000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
87000 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
20000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
39000 usd
CY2023Q1 abmc Accounts Receivable Credit Balances Current
AccountsReceivableCreditBalancesCurrent
0 usd
CY2022Q4 abmc Accounts Receivable Credit Balances Current
AccountsReceivableCreditBalancesCurrent
1000 usd
CY2023Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
188000 usd
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
188000 usd
CY2023Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
114000 usd
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
109000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
90000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
338000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
514000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1690000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1937000 shares
CY2023Q1 abmc Opearting Loss Carry Forward Exipry Notes
OpeartingLossCarryForwardExipryNotes
expire in 2022 and continue to expire through 2038
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
175000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
2230000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
175000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2230000 usd
CY2021Q1 abmc Refund Of Wages
RefundOfWages
202000 usd
abmc Refund Of Wages
RefundOfWages
198000 usd
CY2023Q1 abmc Refund Total Expected
RefundTotalExpected
202000 usd
CY2022Q2 abmc Refund Of Wages
RefundOfWages
199000 usd
CY2022Q2 abmc Claimed As A Refund Amount
ClaimedAsARefundAmount
198000 usd
CY2022Q2 abmc Refund As Interest Amount
RefundAsInterestAmount
1000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
27863899 shares
CY2023Q1 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
47098476 shares
CY2023Q1 abmc Stock Issued During Period Shares Other31
StockIssuedDuringPeriodSharesOther31
the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen.
CY2023Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
3000000 usd
CY2023Q1 us-gaap Lessor Operating Lease Indemnification Payment Received
LessorOperatingLeaseIndemnificationPaymentReceived
300000 usd
CY2023Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
247000 usd
CY2023Q1 us-gaap Proceeds From Loans
ProceedsFromLoans
965000 usd
CY2023Q1 abmc Property Related Taxes Non Current
PropertyRelatedTaxesNonCurrent
193000 usd
CY2023Q1 us-gaap Taxes Other
TaxesOther
12000 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2677000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3209000 usd
CY2023Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2677000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3209000 usd
CY2023Q1 abmc Carry Overs Operating Losses
CarryOversOperatingLosses
1 pure
CY2023Q1 abmc Carry Overs Operating Losses Taxable Income Percentage
CarryOversOperatingLossesTaxableIncomePercentage
0.80 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.21 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.21 pure
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q1 abmc Deferred Tax Assets Inventory Allowance
DeferredTaxAssetsInventoryAllowance
0 usd
CY2022Q4 abmc Deferred Tax Assets Inventory Allowance
DeferredTaxAssetsInventoryAllowance
61000 usd
CY2023Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1000 usd
CY2023Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
138000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
149000 usd
CY2023Q1 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
30000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
21000 usd
CY2023Q1 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
19000 usd
CY2023Q1 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
26000 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
24000 usd
CY2023Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2482000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2972000 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2677000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3209000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
92000 usd
CY2023Q1 abmc Contractually Specified Servicing Fees Amount1
ContractuallySpecifiedServicingFeesAmount1
12000 usd

Files In Submission

Name View Source Status
abmc-20230331_cal.xml Edgar Link unprocessable
0001654954-23-007911-index-headers.html Edgar Link pending
0001654954-23-007911-index.html Edgar Link pending
0001654954-23-007911.txt Edgar Link pending
0001654954-23-007911-xbrl.zip Edgar Link pending
abmc-20230331.xsd Edgar Link pending
abmc_10q.htm Edgar Link pending
abmc_ex311.htm Edgar Link pending
abmc_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
abmc-20230331_pre.xml Edgar Link unprocessable
abmc-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
abmc-20230331_def.xml Edgar Link unprocessable
abmc_10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending